7-Hydroxymitragynine vs MGM-15 vs Mitragynine Pseudoindoxyl: A Comparison
7-Hydroxymitragynine vs MGM-15 vs Mitragynine Pseudoindoxyl — potency comparison, safety risks, and evidence gaps. MGM-15 has the least human data. Harm-reduction focused.
7-Hydroxymitragynine vs MGM-15 vs Mitragynine Pseudoindoxyl: A Comparison
Evidence Snapshot Three compounds related to the kratom alkaloid pathway -- 7-hydroxymitragynine, MGM-15, and mitragynine pseudoindoxyl -- have appeared in unregulated products. All three show higher mu-opioid receptor activity than mitragynine. Human clinical data for these substances is extremely limited.
Strong Disclaimer This article is for informational and educational purposes only. These compounds have little to no human clinical safety data. This is not medical advice. They can carry serious and poorly characterized risks.
TL;DR · Potency Ranking
Based on published binding data: mitragynine pseudoindoxyl > 7-hydroxymitragynine > MGM-15.
Important: MGM-15 has the least human safety data of the three. None are approved for human consumption. This comparison is for harm-reduction information only — proceed with extreme caution.
Introduction
This article provides a cautious comparison of three compounds that have received attention in unregulated markets.
Background
Chemical Information
| Compound | Type | SMILES |
|---|---|---|
| 7-Hydroxymitragynine | Oxidative metabolite | COC1=CC2=C(C=C1O)[C@H]3[C@@H]4CCN(C)[C@H]3[C@H](C2)C4=CC(=O)OC |
| MGM-15 | Semi-synthetic | COC1=CC2=C(C=C1O)[C@H]3[C@@H]4CCN(C)[C@H]3[C@H](C2)C4CC(=O)OC |
| Mitragynine Pseudoindoxyl | Rearrangement product | COC1=CC2=C(C=C1O)[C@H]3[C@@H]4CCN(C)[C@H]3[C@H](C2)C4C(=O)C5=CC=CC=C5O |
Pharmacology and Effects
All three compounds demonstrate activity at opioid receptors. Available laboratory data suggest increasing levels of receptor affinity in this order: 7-hydroxymitragynine < MGM-15 < mitragynine pseudoindoxyl.
Evidence Base
Evidence Grade: Very Low
Human clinical data is extremely limited for all three compounds. Most available information comes from in vitro and animal research.
Safety and Risks
These are opioid-acting substances. Available evidence suggests they carry risks associated with opioid receptor activation, including respiratory depression and physical dependence.
Harm Reduction
- These compounds generally show higher opioid receptor activity than mitragynine.
- Product composition and dosing can be inconsistent or mislabeled.
- Combining these substances with other central nervous system depressants increases risk substantially.
- There is limited reliable information regarding dependence and withdrawal.
Conclusions
These three compounds represent increasing levels of mu-opioid receptor activity. Human safety data remains extremely limited. Significant caution is warranted.
Full Monographs
For the detailed pharmacology, evidence, and safety write-up of each compound:
Related Reading
- Kratom-derived semi-synthetic opioids
- Harm reduction considerations
- Novel psychoactive substances overview
Search Methodology
This comparison draws from peer-reviewed literature, forensic reports, and surveillance data.